← Back to patent-cliff list
Cronexitide lanocianine
Tier C — Watch / tradeCronexitide lanocianine
Integro Theranostics
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
-
Type
Targets：ANXA2
Indications (approved)：Non-small cell lung cancer, Non-invasive ductal carcinoma, Breast cancer, 乳腺导管癌, Lung cancer
Regional status
US
Phase II
2023-07-14
EU
-
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Cronexitide lanocianine?
Approved indications include: Non-small cell lung cancer, Non-invasive ductal carcinoma, Breast cancer, 乳腺导管癌, Lung cancer.
When does the Cronexitide lanocianine patent expire?
No public expiry year is available for Cronexitide lanocianine yet; this page updates once verified.
How do I get a quote for Cronexitide lanocianine intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-21